{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:17:51Z","timestamp":1789582671664,"version":"build-2803163510"},"reference-count":44,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A significant proportion of bronchiectasis patients are chronically infected by potentially pathogenic microorganisms which may lead to frequent exacerbations and worse clinical outcomes. Current bronchiectasis guidelines recommend long-term inhaled antibiotics and\/or oral macrolides as a part of patient management. In recent years, an increasing amount of evidence assessing the impact of these treatments on patient outcomes has been collected. Inhaled antibiotics have demonstrated significant improvements in sputum bacterial load, but their impact on patient quality of life, lung function, and exacerbation rate has not been consistent across trials. In this regard, recent post hoc analyses of inhaled antibiotics trials in bronchiectasis patients have shown that sputum bacterial load may be a key biomarker to predict treatment response in these patients. Oral macrolides, on the other hand, have proven to reduce exacerbation frequency and improve quality of life, but potential drug-related adverse effects and the increase in bacterial resistance are relevant. This review aims to summarize current important evidence for long-term antibiotic treatment in bronchiectasis patients.<\/jats:p>","DOI":"10.1055\/s-0041-1730945","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T22:34:05Z","timestamp":1626302045000},"page":"606-615","source":"Crossref","is-referenced-by-count":4,"title":["Long-Term Antibiotics in Bronchiectasis"],"prefix":"10.1055","volume":"42","author":[{"given":"Guillermo","family":"Suarez-Cuartin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hospital Universitari de Bellvitge, Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Hernandez-Argudo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hospital Universitari de Bellvitge, Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Perea","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), CIBERES, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Sibila","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), CIBERES, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"P A Flume","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"ref2","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"S Finch","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1164\/rccm.201210-1937OC","article-title":"Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation","volume":"187","author":"M M Tunney","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thorax.57.1.15","article-title":"Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors","volume":"57","author":"J Angrill","year":"2002","journal-title":"Thorax"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis","volume":"197","author":"J D Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thoraxjnl-2018-212895","article-title":"Antimicrobial peptides, disease severity and exacerbations in bronchiectasis","volume":"74","author":"O Sibila","year":"2019","journal-title":"Thorax"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S0012","DOI":"10.1016\/j.chest.2020.11.011","article-title":"A cluster analysis of bronchiectasis patients based on the airway immune profile","author":"L Perea","year":"2020","journal-title":"Chest"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"M A Mart\u00ednez-Garc\u00eda","year":"2007","journal-title":"Chest"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1183\/09031936.06.00074605","article-title":"The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis","volume":"28","author":"G Davies","year":"2006","journal-title":"Eur Respir J"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"1701953","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"D Ara\u00fajo","year":"2018","journal-title":"Eur Respir J"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"A M Brodt","year":"2014","journal-title":"Eur Respir J"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"I F Laska","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"E Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbr.2017.07.014","article-title":"Spanish guidelines on treatment of bronchiectasis in adults","volume":"54","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Arch Bronconeumol"},{"issue":"S 01","key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"A T Hill","year":"2019","journal-title":"Thorax"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","article-title":"Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa","volume":"93","author":"R Orriols","year":"1999","journal-title":"Respir Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"A F Barker","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"114S","DOI":"10.1378\/chest.120.3_suppl.114S","article-title":"Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa","volume":"120","author":"L A Couch","year":"2001","journal-title":"Chest"},{"issue":"04","key":"ref19","first-page":"1420","article-title":"A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis","volume":"127","author":"P Scheinberg","year":"2005","journal-title":"Chest"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa","volume":"39","author":"M E Drobnic","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"2001451","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"M R Loebinger","year":"2021","journal-title":"Eur Respir J"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"M P Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"J D Chalmers","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"2003390","DOI":"10.1183\/13993003.03390-2020","article-title":"Reducing Pseudomonas sputum density in bronchiectasis","volume":"57","author":"O Sibila","year":"2021","journal-title":"Eur Respir J"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"A F Barker","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1164\/rccm.201809-1651OC","article-title":"Airway bacterial load and inhaled antibiotic response in bronchiectasis","volume":"200","author":"O Sibila","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"2000608","DOI":"10.1183\/13993003.00608-2020","article-title":"Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies","volume":"56","author":"M L Crichton","year":"2020","journal-title":"Eur Respir J"},{"issue":"09","key":"ref29","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"D J Serisier","year":"2013","journal-title":"Thorax"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"R Wilson","year":"2013","journal-title":"Eur Respir J"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"A De Soyza","year":"2018","journal-title":"Eur Respir J"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"T Aksamit","year":"2018","journal-title":"Eur Respir J"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"C S Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"2000110","DOI":"10.1183\/13993003.00110-2020","article-title":"Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies","volume":"56","author":"J D Chalmers","year":"2020","journal-title":"Eur Respir J"},{"issue":"08","key":"ref35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"C S Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"C Wong","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"J Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"ref38","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"D J Serisier","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"J D Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"03","key":"ref40","first-page":"CD012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"C Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"ref41","first-page":"255","article-title":"PROLONGED antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council","volume":"2","year":"1957","journal-title":"BMJ"},{"issue":"280","key":"ref42","first-page":"799","article-title":"Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis","volume":"76","author":"D C Currie","year":"1990","journal-title":"Q J Med"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/34.1.149","article-title":"Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis","volume":"34","author":"C FJ Rayner","year":"1994","journal-title":"J Antimicrob Chemother"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212468","article-title":"Updated BTS Adult Bronchiectasis Guideline 2018: a multidisciplinary approach to comprehensive care","volume":"74","author":"A T Hill","year":"2019","journal-title":"Thorax"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.chest.2018.01.044","article-title":"Clinical and safety outcomes of long-term azithromycin therapy in severe COPD beyond the first year of treatment","volume":"153","author":"X Pomares","year":"2018","journal-title":"Chest"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1730945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T22:48:53Z","timestamp":1626302933000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1730945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":44,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,7,14]]},"published-print":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1730945","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}